Update: Shiseido has updated its website. The Kobe cell processing and expansion center is now clearly visible on the map. Thanks for the link to commentator “Edgar”.
Shiseido’s Biggest Dot on the Map
Dr. Jiro Kishimoto’s Presentation
I last covered Japan’s cosmetics behemoth Shiseido in early March. This was in my post discussing Replicel’s two important recent announcements. For those who are new to this blog, Shiseido is working on a hair loss cure via its own research as well as via the use and rights to Replicel’s technology in Asia.
A few weeks later, we had the 11th World Congress for Hair Research in Spain. At this Congress, Shiseido (Japan)’s Dr. Jiro Kishimoto had a much anticipated presentation titled: “Autologous cell-based therapy for hair loss using dermal sheath cup cells.”
Shiseido 2019 Update
Several days ago, I got access to the summary of this presentation. Below is the most interesting and important section (with slight grammar changes from my part):
“After a Phase I clinical study with dermal sheath cup (DSC) cells in the EU showed no serious adverse events, we conducted clinical research studies in Japan on autologous cell based therapy for 66 male and female patients with androgenic alopecia using DSC cells. The study is currently ongoing at two medical institutions and no serious adverse effects have been reported thus far.
I would also like to discuss a unique registration law for cell therapy in Japan. This law enables hospitals and clinics to outsource cell and tissue processing to specialized cell processing facilities (CPC) located outside hospitals. We have introduced a cell manufacturing process for DSC cells in the CPC established in Kobe by ourselves, and I will discuss future prospects for cell-therapy in patients with AGA.”
Besides typical delays, Replicel and Shiseido had some unclear conflicts regarding 